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Abstract 
 
Background: The New Approach riVaroxaban Inhibition of Factor Xa in a Global trial vs. ASA to 
prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is an 
international randomized phase III trial comparing rivaroxaban versus aspirin in patients with recent 
ESUS. While these patients share the common stroke mechanism of ESUS, they likely vary with 
respect to the underlying potential embolic sources. 
Aims:  We aimed to describe the baseline characteristics of this large ESUS cohort in order to 
explore their relationships among key subgroups. 
Methods: We enrolled 7214 patients at 459 sites in 31 countries. Pre-specified subgroup analyses for 
the primary safety and efficacy outcomes included age, sex, race, global region, stroke or TIA prior to 
qualifying event, time from qualifying stroke to randomization, hypertension, and diabetes mellitus. 
Results: The mean age was 66.9±9.8 years, and 24% were <60 years old. Older patients had more 
hypertension, coronary disease, and cancer. Strokes in older subjects were more frequently cortical 
and accompanied by radiographic evidence of prior infarction.  Women comprised 38% of 
participants and were older than men.  Patients from East Asia were oldest while those from Latin 
America were youngest. Patients in the Americas more frequently were on aspirin prior to the 
qualifying stroke.  Acute infarction involving the cortex was more common in the U.S.A., Canada, 
and Western Europe, while prior infarctions in addition to the index stroke were most commonly 
observed in East Asia. About 45% of subjects were enrolled within 30 days of the qualifying stroke, 
with the earliest enrollments in Asia and Eastern Europe.   
Conclusions: NAVIGATE ESUS is the largest randomized trial comparing antithrombotic strategies 
for secondary stroke prevention in patients with embolic strokes of undetermined source.  The study 
population encompasses a broad array of patients across multiple continents and these subgroups 
provide ample opportunities for future research.  
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Introduction 
 
Embolic stroke of undetermined source (ESUS) is a subset of cryptogenic stroke, and a diagnostic 
label proposed for an ischemic stroke that occurs without an identifiable and specifically treatable 
underlying stroke etiology, including >50% stenosis in a large proximal artery in the territory of 
ischemia, atrial fibrillation or other major-risk cardioembolic source, lacunar (small vessel occlusive) 
disease, or identified uncommon cause.1 ESUS accounts for 15 to 30% of all ischemic strokes.2 A 
wide range of potential cardiac, arterial, paradoxical, and hematological sources have been proposed 
that might be amenable to treatment with an anticoagulant.1, 3, 4 The New Approach riVaroxaban 
Inhibition of Factor Xa in a Global trial vs. ASA to prevenT Embolism in Embolic Stroke of 
Undetermined Source (NAVIGATE-ESUS) trial is an international randomized phase III trial 
comparing rivaroxaban with aspirin in patients with recent ESUS. The design of the trial has 
previously been reported,5 enrollment of 7214 subjects has recently been completed, and participant 
features are reported here. 
 
While the NAVIGATE-ESUS participants share a common diagnosis of ESUS, they likely vary with 
respect to the underlying potential embolic sources,6 and therefore subgroup analyses may be 
especially important.7, 8  Subgroup analysis in clinical trials is often performed for two key purposes. 
One major goal is to explore the consistency of a treatment effect among different subpopulations 
that are defined at baseline. The other is to investigate whether there are specific groups that are 
more or less likely to receive benefit or harm from the treatment. Together, these assessments of 
both homogeneity and heterogeneity can yield valuable information for clinicians and future 
research, but these analyses must be interpreted cautiously, mitigated by reduced statistical power 
and the play of chance.9 Subgroup analysis can also help identify populations at greatest risk of a 
recurrent event.  Clinical characteristics of selected subgroups pre-specified in the NAVIGATE 
ESUS trial statistical analysis plan are provided. 
 
Methods: 
 
NAVIGATE ESUS Study design 
The design of NAVIGATE ESUS (clinicaltrials.gov.NCT02313909) has previously been published.5 
In brief, it is an international, double-blinded, randomized phase III superiority trial comparing 
rivaroxaban 15 mg once daily (immediate-release, film-coated tablets) with aspirin (enteric-coated) 
100 mg once daily, both to be taken with food, in patients with recent ESUS.  Target enrollment was 
approximately 7000, and the study was designed to continue until at least 450 primary events have 
occurred. Key eligibility criteria for NAVIGATE ESUS are summarized in the Appendix 
(Supplement Table 1). The primary efficacy outcome is time to recurrent stroke, comprising ischemic, 
hemorrhagic and undefined stroke, including TIAs with positive neuroimaging10 or systemic 
embolism.  The primary safety outcome is major bleeding as defined by the criteria of the 
International Society of Thrombosis and Haemostasis.11 The main efficacy and safety results will be 
available in 2018. 
 
Baseline characteristics and subgroup analyses 
Baseline characteristics collected in the trial include demographic features, medical history, qualifying 
stroke information, and baseline functional and cognitive status. Pre-specified participant subgroup 
analyses for which the treatment effects will be presented in the main results publication were chosen 
for presentation here, in accord with the statistical analysis plan.  These included the following, based 
on the data collected at the time of randomization: age, sex, race, global region, stroke or TIA prior to 
qualifying event, time from qualifying stroke to randomization, hypertension, and diabetes mellitus. 
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Statistical analysis 
We describe the features of all subjects and compare the baseline characteristics for selected pre-
specified subgroups. Descriptive statistics use mean ± standard deviation, median (interquartile range 
[IQR]), or proportion as appropriate. Univariate comparisons were made using t-tests for continuous 
variables and chi- squared tests for categorical variables, and we present nominal two-sided p-values. 
For comparisons within subgroups, we consider only p values <0.01 to be significant to account for 
the multiple comparisons. 
 
Results 
 
A total of 7214 subjects were randomized in the NAVIGATE ESUS trial between December 24, 
2014 and September 20, 2017. The major baseline characteristics for the entire study population are 
summarized in Table 1. The mean age was 66.9 ± 9.8 years, and 62% were men.  Median baseline 
NIHSS score was 1 (IQR 0, 2) and was ≤5 in 96% of patients. All subjects had extracranial vascular 
imaging, echocardiography, and initial cardiac rhythm monitoring as required by protocol, and 78% 
had intracranial vascular imaging.  Forty-three percent (43%) of patients were enrolled from Western 
Europe (Figure).  Characteristics of pre-specified selected subgroups are summarized in Tables 2 to 4 
and the Supplemental Tables.  Key differences among subgroups are described below.  Of note, only 
7% of participants had a history of coronary artery disease due to protocol stipulation excluding 
patients who require single or dual antiplatelet therapy.   
 
Age. As summarized in Table 2, 24% of patients were under 60 and 21% were older than 75 years. 
Older subjects were more likely to be women, of white race, and had lower weight and BMI values as 
well as lower estimated glomerular filtration rates. Older subjects had a greater burden of 
hypertension, coronary artery disease, cancer, but there were fewer smokers and less diabetes. 
Cognitive function as assessed by the Montreal Cognitive Assessment (MoCA) was more impaired 
with increasing age. Aspirin use prior to the qualifying stroke was more common with increasing age. 
The qualifying strokes in older subjects more frequently involved the cerebral cortex and were more 
often accompanied by evidence of prior or chronic infarcts observed on neuroimaging. 
 
Sex. As shown in Table 3, compared to men, the 39% of subjects who were women were older, more 
likely to be white and less likely to be Asian. Women had lower weight but slightly greater BMI than 
men.  Women had modestly more hypertension but were less likely to be current smokers. Women 
were more commonly treated with acute thrombolysis or endovascular therapy. 
 
Region.  As summarized in Table 4, patients enrolled in Western Europe tended to be the oldest. 
Smoking was more common in Eastern Europe and East Asia.  Patients in the Americas were more 
likely to be on aspirin prior to the qualifying stroke than those from Europe and East Asia.  Patients 
were less likely to be treated with thrombolysis for the qualifying stroke in Latin America and East 
Asia. Acute cortical infarction was more common in North America and Western Europe, while 
chronic infarctions in addition to the index stroke were most commonly observed in East Asia. 
 
Race. The majority of subjects were white (72%) or Asian (20%). Variability in baseline characteristics 
by race are shown in Supplemental Table 2, with notably lower BMI values among Asians and more 
current tobacco use. Asians also appeared more likely to have subcortical infarctions, more chronic 
infarctions, and suffered less disability from their strokes (mRS 0-1). Blacks were enrolled mainly in 
the Americas and had the highest prevalence of hypertension. 
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Hypertension. A history of hypertension was reported in 77% of subjects, and was associated with 
older age and the presence of diabetes and coronary artery disease, as shown in Supplemental table 3. 
Patients with hypertension were more likely to be taking aspirin prior to the qualifying stroke, had 
more evidence of chronic radiographic infarction, and mildly lower MoCA scores. 
 
Diabetes mellitus. Diabetes mellitus was present in 25% of subjects at enrollment and characteristics 
are summarized in Supplemental Table 4.  Patients with diabetes were younger, had greater BMI 
values, and were more likely to have hypertension, coronary disease, prior stroke as well as chronic 
radiographic infarction, and mildly lower MoCA scores. Aspirin use prior to the index stroke was 
more common and thrombolysis use less common in patients with diabetes. 
 
Stroke or TIA prior to index event. As shown in Supplemental Table 5, 17% of subjects had a prior 
clinical stroke or TIA.  These patients were similar with respect to demographic features, but had a 
greater burden of coronary artery disease. Aspirin use prior to the index stroke and chronic infarcts 
on imaging were more than twice as common in this group, and they had slightly lower MoCA 
scores. 
 
Time from qualifying stroke to randomization. As indicated in Supplemental Table 6, 45% of subjects were 
enrolled within 30 days of the qualifying stroke, 31% between 30 and 90 days, and 24% between 3 
and 6 months. Patients in East Asia and Eastern Europe were enrolled earlier than in other regions.   
 
Discussion 
 
NAVIGATE ESUS is the largest randomized trial comparing antithrombotic therapeutic strategies 
for secondary stroke prevention in patients with ESUS. The study population encompasses a wide 
spectrum of patients across multiple continents. Moreover, the population is similar to published 
smaller cohorts of patients with cryptogenic stroke or ESUS,2, 12-15 supporting the external validity and 
generalizability of the ESUS concept and its implementation in this trial. 
 
The hypothesis of the NAVIGATE-ESUS trial is that rivaroxaban would be associated with a 
substantially lower risk of recurrent embolic events without a clinically unacceptable increase of 
major hemorrhages relative to aspirin, with relatively consistent treatment effects across the 
subgroups described here. However, higher event rates would be anticipated for older patients, 
women, and those with stroke or TIA prior to qualifying event, hypertension, and diabetes. Observed 
baseline differences across subgroups may be important in the assessment of treatment effects within 
these groups. Some of these are potentially relevant confounders, such as the relationships between 
older age and prior antiplatelet agent use, or between global region and time from qualifying event to 
randomization, because those relationships within subgroups could also be associated with outcome 
events. Others are statistically significant relationships that are unlikely to confound a treatment 
effect, such as the apparent relationship between smoking and time from the qualifying event, but 
nevertheless provide important descriptions of the cohort.  The relevance of these factors will need 
to be weighed in the context of the overall and subgroup analyses of treatment effects in 
NAVIGATE ESUS, which are anticipated in the near future. Further, these data will provide a 
robust opportunity to determine if different ESUS subgroups have varying risks of recurrent stroke 
and other major vascular events.  ESUS is a broad definition and description of the full cohort across 
multiple baseline characteristics helps to understand the inherent heterogeneity and perhaps guide 
future trials about optimal patient selection. 
 
This study has potential limitations.  Despite the large size of NAVIGATE cohort, it represents 
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patients who are willing and able to participate in a clinical trial and therefore may be subject to 
limitations on generalizability, both overall and within these subgroups. Differences in the acute 
treatment of stroke and variations in risk factors based on racial and genetic predispositions may 
introduce heterogeneity among these subgroups. Further, diagnostic testing may affect outcome 
analysis as patients in higher income countries may have undergone more extensive pre-enrollment 
investigation than those in middle or lower income countries.  
 
NAVIGATE ESUS is the largest randomized trial in ESUS and the first to address new paradigms 
for stroke diagnosis and prevention. The results, particularly in key subgroups, are expected to 
shed new light on the treatment and prognosis of ESUS.  
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Table 1. Baseline characteristics of the complete NAVIGATE-ESUS study 
population 
 
Characteristic N with Data 
Summary 
(N=7214) 
Age, years (mean ± s.d.) 7214 66.9 ± 9.8 
 Age<60 years  24% 
Male sex 7214 62% 
Race: 7206  
 White only  72% 
 Black only  2% 
 Asian only  20% 
 Others (includes not reported/multiracial)  6% 
BMI, kg/m2 (mean ± s.d.) 7179 27.2 ± 5.0 
 <25 kg/m2  35% 
 ≥25 - <30 kg/m2  41% 
 ≥30 kg/m2  24% 
 <30 kg/m2  76% 
 ≥30 kg/m2  24% 
Weight, kg (mean ± s.d.) 7186 76.2 ± 16.6 
 <70 kg  35% 
 70 - 90 kg  48% 
 >90 kg  16% 
 <50 kg  3% 
 50 - 100 kg  90% 
 >100 kg  7% 
Estimated glomerular filtration rate (eGFR), mL/min per 1.73 m2 7190 78.6 ± 20.6 
 <50 mL/min  6% 
 50 - 80 mL/min  49% 
 >80 mL/min  45% 
Medical history:   
 Hypertension 7209 77% 
 Diabetes mellitus 7209 25% 
 Current tobacco use 7206 21% 
 Coronary artery disease 7209 7% 
 Heart failure 7209 3% 
 Cancer 7209 9% 
 Prior stroke or TIA 7209 17% 
Global region:   
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Characteristic N with Data 
Summary 
(N=7214) 
 U.S.A. and Canada 7214 13% 
 Latin America  10% 
 Western Europe  43% 
 Eastern Europe  16% 
 East Asia  19% 
Qualifying stroke:   
Clinical TIA with imaging-confirmed infarction as qualifying event: 7214 7% 
Arterial territory of qualifying stroke:* 7214  
 Anterior circulation  72% 
 Posterior circulation  31% 
Location of qualifying stroke: 7214  
 Single Location:   
  Cerebral hemisphere with cortical involvement  56% 
  Cerebral hemisphere, subcortical only  21% 
  Brainstem only  5% 
  Cerebellum only  8% 
 Multiple Locations:  10% 
Chronic infarct on imaging (in addition to index stroke) 7200 32% 
Aspirin use prior to qualifying stroke 7214 17% 
Treated with intravenous tPA for qualifying stroke 7206 17% 
Treated with endovascular intervention for qualifying stroke 7206 4% 
NIHSS score at randomization (median, IQR) 7201 1.0 (0.0, 2.0) 
 NIHSS score ≤5  96% 
Modified Rankin Scale (mRS) at randomization: 7203  
 mRS 0 or 1  65% 
 mRS 2  23% 
 mRS ≥3  12% 
MoCA score at randomization (median, IQR) 5787 25.0 (21.0, 27.0) 
Time from qualifying stroke to randomization, days (median, IQR) 7202 37.0 (14.0, 88.0) 
Extracranial vascular imaging completed:   
 CTA 7206 38% 
 MRA 7203 33% 
 Carotid ultrasound 7205 63% 
 Conventional angiography 5576 2% 
Intracranial vascular imaging completed: 7214  
 CTA but not MRA or Transcranial Doppler  36% 
 MRA but not Transcranial Doppler  30% 
  
11  
Characteristic N with Data 
Summary 
(N=7214) 
 Transcranial Doppler  12% 
 None  22% 
Transthoracic echocardiography: 7203 95% 
 Left atrial diameter, cm (mean ± s.d.) 3973 3.8 ± 1.9 
 Left ventricular ejection fraction, % (mean ± s.d.) 5744 62.3 ± 8.1 
Transesophageal echocardiography 7201 19% 
 Patent foramen ovale present 1383 27% 
Duration of cardiac rhythm monitoring ≥48 hours 7187 34% 
*Arterial territory could be multiple, resulting in a total>100% 
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Table 2. Comparisons by Age 
 
Characteristic 
<60 yrs 
(N=1716) 
60 - 75 yrs 
(N=4013) 
>75 yrs 
(N=1485) p^ 
Age, years (mean ± s.d.) 54.1 ± 4.5 67.4 ± 4.4 80.5 ± 3.7  
Male sex 71% 63% 47% <.001 
Race:     
 White only 67% 73% 77% <.001 
 Black only 3% 1% 1% <.001 
 Asian only 24% 19% 16% <.001 
 Others (includes not reported/multiracial) 7% 6% 6% 0.38 
BMI, kg/m2 (mean ± s.d.) 27.9 ± 5.5 27.3 ± 5.0 26.3 ± 4.5 <.001 
Weight, kg (mean ± s.d.) 80.5 ± 17.3 76.7 ± 16.3 69.9 ± 14.5 <.001 
Estimated glomerular filtration rate (eGFR), mL/min per 1.73 m2 88.1 ± 21.0 78.7 ± 19.4 67.5 ± 17.4 <.001 
Medical history:     
 Hypertension 78% 75% 83% 0.001 
 Diabetes mellitus 26% 25% 22% 0.009 
 Current tobacco use 38 19% 5% <.001 
 Coronary artery disease 5% 6% 9% <.001 
 Heart failure 4% 3% 4% 0.80 
 Cancer 3% 9% 15% <.001 
 Prior stroke or TIA 19% 16% 21% 0.40 
Global region:     
 U.S.A. and Canada 15% 13% 11% 0.003 
 Latin America 10% 11% 9% 0.45 
 Western Europe 35% 42% 55% <.001 
 Eastern Europe 18% 17% 9% <.001 
 East Asia 23% 18% 16% <.001 
Qualifying stroke:     
Clinical TIA with imaging-confirmed infarction as qualifying event: 6% 8% 8% 0.03 
Arterial territory of qualifying stroke:*     
 Anterior circulation 71% 71% 74% 0.15 
 Posterior circulation 31% 31% 30% 0.54 
Location of qualifying stroke:     
 Single Location:     
  Cerebral hemisphere with cortical involvement 48% 56% 62% <.001 
  Cerebral hemisphere, subcortical only 27% 21% 15% <.001 
  Brainstem only 5% 5% 3% 0.003 
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  Cerebellum only 9% 8% 8% 0.50 
 Multiple Locations: 11% 10% 12% 0.32 
Chronic infarct on imaging (in addition to index stroke) 31% 32% 37% <.001 
Aspirin use prior to qualifying stroke 13% 17% 24% <.001 
Treated with intravenous tPA for qualifying stroke 16% 18% 17% 0.35 
Treated with endovascular intervention for qualifying stroke 4% 4% 4% 0.83 
NIHSS score at randomization (median, IQR) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) <.001 
Modified Rankin Scale (mRS) at randomization:     
 mRS 0 or 1 63% 67% 59% 0.02 
 mRS 2 25% 22% 24% 0.33 
 mRS ≥3 11% 11% 17% <.001 
MoCA score at randomization (median, IQR) 26.0 (22.0, 28.0) 25.0 (21.0, 27.0) 22.0 (18.0, 26.0) <.001 
Time from qualifying stroke to randomization, days (median, IQR) 35.0 (14.0, 87.0) 38.0 (15.0, 90.0) 35.5 (13.5, 85.5) 0.43 
 
*Arterial territory could be multiple, resulting in a total>100% 
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Table 3. Comparisons by Sex 
 
Characteristic 
Male 
(N=4437) 
Female 
(N=2777) p value^ 
Age, years (mean ± s.d.) 65.6 ± 9.4 69.1 ± 10.0 <.001 
 Age<60 years 27% 18% <.001 
Race:    
 White only 70% 76% <.001 
 Black only 1% 2% 0.40 
 Asian only 22% 16% <.001 
 Others (includes not reported/multiracial) 6% 7% 0.64 
BMI, kg/m2 (mean ± s.d.) 27.1 ± 4.6 27.5 ± 5.7 <.001 
Weight, kg (mean ± s.d.) 80.2 ± 15.7 69.7 ± 15.8 <.001 
Estimated glomerular filtration rate (eGFR), mL/min per 1.73 m2 80.7 ± 20.6 75.4 ± 20.0 <.001 
Medical history:    
 Hypertension 75% 81% <.001 
 Diabetes mellitus 26% 23% 0.009 
 Current tobacco use 26% 12% <.001 
 Coronary artery disease 7% 5% 0.004 
 Heart failure 3% 3% 0.26 
 Cancer 8% 9% 0.22 
 Prior stroke or TIA 17% 19% 0.01 
Global region:    
 U.S.A. and Canada 12% 14% 0.02 
 Latin America 9% 12% <.001 
 Western Europe 42% 44% 0.20 
 Eastern Europe 15% 16% 0.93 
 East Asia 21% 15% <.001 
Qualifying stroke:    
Clinical TIA with imaging-confirmed infarction as qualifying event: 8% 7% 0.57 
Arterial territory of qualifying stroke:*    
 Anterior circulation 71% 74% 0.001 
 Posterior circulation 33% 29% <.001 
Location of qualifying stroke:    
 Single Location:    
  Cerebral hemisphere with cortical involvement 55% 57% 0.07 
  Cerebral hemisphere, subcortical only 21% 21% 0.77 
  Brainstem only 5% 4% 0.30 
  Cerebellum only 8% 8% 0.32 
 Multiple Locations: 11% 10% 0.11 
Chronic infarct on imaging (in addition to index stroke) 33% 31% 0.06 
Aspirin use prior to qualifying stroke 17% 18% 0.18 
Treated with intravenous tPA for qualifying stroke 16% 19% 0.005 
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Characteristic 
Male 
(N=4437) 
Female 
(N=2777) p value^ 
Treated with endovascular intervention for qualifying stroke 3% 5% <.001 
NIHSS score at randomization (median, IQR) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 0.77 
Modified Rankin Scale (mRS) at randomization:    
 mRS 0 or 1 67% 62% <.001 
 mRS 2 22% 24% 0.05 
 mRS ≥3 11% 14% 0.002 
MoCA score at randomization (median, IQR) 25.0 (21.0, 27.0) 24.0 (20.0, 27.0) <.001 
Time from qualifying stroke to randomization, days (median, IQR) 36.0 (14.0, 90.0) 37.0 (15.0, 85.0) 0.77 
*Arterial territory could be multiple, resulting in a total>100% 
 
 
  
 
Table 4. Comparisons by global region 
 
Characteristic 
U.S.A. & Canada 
(N=918) 
Latin America 
(N=746) 
Western Europe 
(N=3081) 
Eastern Europe 
(N=1119) 
East Asia 
(N=1350) p value^ 
Age, years (mean ± s.d.) 66.2 ± 9.8 66.4 ± 10.0 68.7 ± 9.8 64.7 ± 8.5 65.6 ± 10.1 <.001 
 Age<60 years 27% 24% 19% 27% 29% <.001 
Male sex 58% 56% 61% 61% 69% <.001 
Race:       
 White only 85% 82% 88% 100% 0% <.001 
 Black only 6% 4% 1% 0% 0% <.001 
 Asian only 5% 0% 1% 0% 100% <.001 
 Others (includes not reported/multiracial) 4% 14% 10% 0% 0% <.001 
BMI, kg/m2 (mean ± s.d.) 29.3 ± 6.4 28.1 ± 4.6 27.5 ± 4.8 28.3 ± 4.5 23.9 ± 3.5 <.001 
Weight, kg (mean ± s.d.) 83.4 ± 19.2 74.5 ± 14.5 78.1 ± 15.7 81.1 ± 14.6 63.8 ± 11.7 <.001 
Estimated glomerular filtration rate (eGFR), mL/min per 1.73 m2 73.3 ± 17.8 81.2 ± 22.1 77.5 ± 19.2 78.6 ± 20.1 83.5 ± 23.4 <.001 
Medical history:       
 Hypertension 73% 83% 76% 89% 71% <.001 
 Diabetes mellitus 24% 31% 22% 27% 26% <.001 
 Current tobacco use 17% 13% 18% 25% 29% <.001 
 Coronary artery disease 13% 4% 5% 10% 4% <.001 
 Heart failure 3% 2% 3% 9% 1% <.001 
 Cancer 13% 5% 10% 4% 7% <.001 
 Prior stroke or TIA 23% 18% 16% 14% 18% <.001 
Qualifying stroke:       
Clinical TIA with imaging-confirmed infarction as qualifying event: 8% 6% 9% 3% 7% <.001 
Arterial territory of qualifying stroke:*       
 Anterior circulation 71% 71% 72% 70% 73% 0.46 
  
Characteristic 
U.S.A. & Canada 
(N=918) 
Latin America 
(N=746) 
Western Europe 
(N=3081) 
Eastern Europe 
(N=1119) 
East Asia 
(N=1350) p value^ 
 Posterior circulation 33% 31% 30% 30% 35% 0.01 
Location of qualifying stroke:       
 Single Location:       
  Cerebral hemisphere with cortical involvement 65% 55% 64% 46% 39% <.001 
  Cerebral hemisphere, subcortical only 13% 25% 14% 33% 30% <.001 
  Brainstem only 2% 8% 3% 7% 6% <.001 
  Cerebellum only 8% 7% 9% 8% 8% 0.58 
 Multiple Locations: 12% 5% 10% 6% 17% <.001 
Chronic infarct on imaging (in addition to index stroke) 28% 34% 27% 37% 43% <.001 
Aspirin use prior to qualifying stroke 21% 23% 18% 16% 11% <.001 
Treated with intravenous tPA for qualifying stroke 21% 8% 22% 18% 8% <.001 
Treated with endovascular intervention for qualifying stroke 8% 1% 5% 2% 3% <.001 
NIHSS score at randomization (median, IQR) 0.0 (0.0, 1.0) 2.0 (1.0, 4.0) 0.0 (0.0, 2.0) 2.0 (0.0, 3.0) 1.0 (0.0, 2.0) <.001 
Modified Rankin Scale (mRS) at randomization:       
 mRS 0 or 1 69% 55% 67% 57% 70% <.001 
 mRS 2 22% 29% 22% 28% 19% <.001 
 mRS ≥3 8% 16% 11% 16% 11% <.001 
MoCA score at randomization (median, IQR) 26.0 (23.0, 28.0) 23.0 (17.0, 26.0) 25.0 (21.0, 27.0) 25.0 (22.0, 27.0) 23.0 (20.0, 26.0) <.001 
Time from qualifying stroke to randomization, days (median, IQR) 70.0 (41.0, 123.0) 54.0 (31.0, 102.0) 42.0 (14.0, 101.0) 23.0 (13.0, 56.5) 18.0 (11.0, 38.0) <.001 
*Arterial territory could be multiple, resulting in a total>100% 
 
 
  
 
 
 
Figure Legend. 
 
Figure 1.  Enrollment by global region in the NAVIGATE-ESUS trial.  
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